CEPHEID (CPHD) : The highest level CEPHEID (CPHD) is projected to reach is $47 for the short term and the lowest estimate is at $30. The consolidated price target from 11 rating analysts who initiate coverage on the stock is $39.09 and the possibility the share price can swing is $5.22.
CEPHEID (CPHD) has an average broker rating of 2.07, which is interpreted as a Buy, as rated by 14 equity analysts. Nonetheless, 6 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. 1 other analysts advise a Buy. Nevertheless, the majority of 7 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 2, which is also a Buy.
Also, Equity Analysts at the Brokerage Firm, Jefferies, maintains their rating on the shares of CEPHEID (NASDAQ:CPHD). Jefferies has a Hold rating on the shares. As per the latest research report, the brokerage house raises the price target to $34 per share from a prior target of $28. The rating by the firm was issued on August 17, 2016.
CEPHEID (NASDAQ:CPHD): The stock opened at $34.36 on Thursday but the bulls could not build on the opening and the stock topped out at $34.86 for the day. The stock traded down to $34.00 during the day, due to lack of any buying support eventually closed down at $34.26 with a loss of -0.17% for the day. The stock had closed at $34.32 on the previous day. The total traded volume was 432,770 shares.
Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the clinical market and non-clinical markets. Its systems enable molecular testing for organisms and genetic-based diseases. Molecular testing involves various time-intensive steps, including sample preparation, DNA amplification and detection. The Companys systems integrate these steps and analyze biological samples in test cartridges. Its primary offering is the GeneXpert system, which integrates sample preparation in addition to DNA amplification and detection, serves reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals, as well as physician offices and other alternate site laboratories. It also offers the SmartCycler system, which integrates DNA amplification and detection to allow rapid analysis of a sample.